From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 ...

inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online October 23 in the Journal of the American Medical Association. Piaopiao Li, from the Emory ...

MONDAY, Oct. 28, 2024 (HealthDay News) — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

MONDAY, Oct. 28, 2024 (HealthDay News) -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

Tyra Biosciences (NASDAQ:TYRA) is gearing up to report data from its phase 1/2 study, using its FGFR3-inhibitor TYRA-300 ... service on Seeking Alpha Marketplace. If you like what you read here ...

Over the last decade, TNF-α antagonists became the most powerful tools for controlling patient suffering from a number of rheumatic diseases. Infliximab, etanercept and adalimumab can induce ...

In fact, sotagliflozin is marked as an "other SGLT2 inhibitor," with uncertainty regarding its impact on HFrEF in patients without diabetes. This is an important notation, as many heart failure ...